Cytovation is a biotechnology company pioneering a novel class of bifunctional peptide therapeutics that target tumors with immune-excluded microenvironments. Its lead candidate, CY-101, is a synthetic peptide designed to selectively target cancer cell membranes via their negative surface charge, forming pores that expose intact neoantigens and trigger a tumor-specific immune response. Simultaneously, CY-101 uniquely inhibits the Wnt/β-catenin pathway by activating Axin2, a negative feedback regulator in the β-catenin destruction complex. This dual mechanism addresses both local tumor clearance and systemic immune suppression, overcoming resistance to checkpoint inhibitors. CY-101 is currently in a registrational Phase 2 trial for adrenocortical carcinoma (ACC) in collaboration with Cancer Research UK. The company is now raising a Series B to expand into high-prevalence β-catenin-driven tumors such as colorectal cancer (CRC) and hepatocellular carcinoma (HCC).